CHRNA7 is a neurodevelopmental protein involved in differentiation and neurogenesis, which is also named as nicotinic acetylcholine receptors, cholinergic receptor, nicotinic, alpha 7 (neuronal). The protein encoded by this gene forms a homo-oligomeric channel. It is a major component of brain nicotinic receptors displays that are blocked by and sensitive to alpha-bungarotoxin. Studies reports involvement of CHRNA7 protein in different neurological diseases. Non-availability of 3-dimensional (3D) structure leads the study toward structure 3D prediction along with its interaction analysis. The current paper is focused on the structure prediction through homology modeling of CHRNA7 along with binding site prediction using Schrödinger software suite. In continuation of the study, protein-protein interaction analysis is carried out by using string database. Tertiary structure along with binding sites was obtained, and visualized CHRAN7 protein have interaction with CHRNA protein family along with JAK2, AKT1, PICK1 protein that are involved in neurological disease. Structure formation analysis is an important aspect of proteomics studies. Hence, this predicted structure can be used for further advance studies and drug designing. Protein interaction analysis shows that CHRNA7 protein also interact with AKT1 protein which regulate neuronal differentiation and development, that signifies the role of CHRNA7 protein in neurological diseases.

Keywords:
CHRNA7, Neuronal development disease, Homology modeling, Schrodinger software, Protein interaction
1.
Elliott KJ, et al: Comparative structure of human neuronal 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits. J Mol Neurosci 1996;7:217-228.
2.
Carson R, et al: Genetic variation in the α7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromolecular Med 2008;10:377-384.
3.
Schulz-Gasch T, Stahl M: Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J Mol Model 2003;9:47-57.
4.
Release, Schrödinger. ‘1: SiteMap, version 1.7.' New York, Schrödinger, LLC, 2010.
5.
Schrödinger, Prime. ‘Version 3.5.' New York, LLC, 2014.
6.
Release, Schrödinger. ‘2: Prime, version 3.' New York, Schrödinger, LLC, 2013.
7.
Tsutsumi Y: Schrodinger equation. Funkcialaj Ekvacioj 1987;30:115-125.
8.
Adedeji AO, Singh K, Sarafianos SG: Structural and biochemical basis for the difference in the helicase activity of two different constructs of SARS-CoV helicase. Cell Mole Biol (Noisy-le-Grand) 2012;58:114-121.
9.
Nayeem A, Sitkoff D, Krystek S Jr: A comparative study of available software for high-accuracy homology modeling: from sequence alignments to structural models. Protein Sci 2006;15:808-824.
10.
Ivanov AA, Barak D, Jacobson KA: Evaluation of homology modeling of G protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. J Med Chem 2009;52:3284-3292.
11.
Singh KD, et al: Homology modeling, molecular dynamics, e-pharmacophore mapping and docking study of Chikungunya virus nsP2 protease. J Mol Model 2012;18:39-51.
12.
Leonard S, et al: Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002;59:1085-1096.
13.
Xu J, et al: Evidence for linkage disequilibrium between the alpha 7 - nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. Am J Med Genet 2001;105:669-674.
14.
Dempster EL, et al: Episodic memory performance predicted by the 2bp deletion in exon 6 of the “alpha 7-like” nicotinic receptor subunit gene. Am J Psychiatry 2006;163:1832-1834.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.